A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Trial Details
- NCT ID
- NCT06942442
- Phase
- PHASE2
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Status
- RECRUITING
- Cancer Type
- Sarcoma
- Interventions
- Physician's Choice
- Tebentafusp
- Locations (sample)
- Los Angeles, California, United States|34.05223,-118.24368
- Chicago, Illinois, United States|41.85003,-87.65005
- New York, New York, United States|40.71427,-74.00597
- London, United Kingdom|51.50853,-0.12574
Key Eligibility Criteria
- Age 18 years
- Histologically confirmed diagnosis of HMB-45+ clear cell sarcoma which is unresectable and/or metastatic
- HLA-A\*02:01 positive
- ECOG Performance Status of £ 2 at screening
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →